| Athanasios Vlahos, MD | |
|
911 N Elm St, Ste 128, Hinsdale, IL 60521-3634 | |
| (630) 856-7460 | |
| (630) 655-9943 |
| Full Name | Athanasios Vlahos |
|---|---|
| Gender | Male |
| Speciality | Interventional Radiology |
| Experience | 25 Years |
| Location | 911 N Elm St, Hinsdale, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588617757 | NPI | - | NPPES |
| 158617757 | Other | IL | GROUP NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | 036110155 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advocate Trinity Hospital | Chicago, IL | Hospital |
| Adventist La Grange Memorial Hospital | La grange, IL | Hospital |
| Adventist Hinsdale Hospital | Hinsdale, IL | Hospital |
| Adventist Glenoaks | Glendale heights, IL | Hospital |
| Advocate Sherman Hospital | Elgin, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vascular And Interventional Professionals, Llc | 2365758224 | 18 |
News Archive
St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.
Direct-to-consumer advertising for commercial genetic testing is on the rise and may be problematic, according to a Massachusetts General Hospital (MGH) physician. In the December issue of Obstetrics & Gynecology, Erin Tracy, MD, MPH, warns that such testing is poorly regulated and may present potential pitfalls for patients and physicians.
The idea of testing blood or urine to find markers that help diagnose or treat disease holds great promise. But as technology has improved to allow researchers to examine tiny fragments of RNA, one major problem has led to limited success.
Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.
› Verified 7 days ago
| Entity Name | Nephrology Associates Of Northern Illinois Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124069182 PECOS PAC ID: 2163328675 Enrollment ID: O20031208000313 |
News Archive
St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.
Direct-to-consumer advertising for commercial genetic testing is on the rise and may be problematic, according to a Massachusetts General Hospital (MGH) physician. In the December issue of Obstetrics & Gynecology, Erin Tracy, MD, MPH, warns that such testing is poorly regulated and may present potential pitfalls for patients and physicians.
The idea of testing blood or urine to find markers that help diagnose or treat disease holds great promise. But as technology has improved to allow researchers to examine tiny fragments of RNA, one major problem has led to limited success.
Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.
› Verified 7 days ago
| Entity Name | Willow Springs Surgery Center Ltd |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1467429233 PECOS PAC ID: 5092783712 Enrollment ID: O20040921000585 |
News Archive
St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.
Direct-to-consumer advertising for commercial genetic testing is on the rise and may be problematic, according to a Massachusetts General Hospital (MGH) physician. In the December issue of Obstetrics & Gynecology, Erin Tracy, MD, MPH, warns that such testing is poorly regulated and may present potential pitfalls for patients and physicians.
The idea of testing blood or urine to find markers that help diagnose or treat disease holds great promise. But as technology has improved to allow researchers to examine tiny fragments of RNA, one major problem has led to limited success.
Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.
› Verified 7 days ago
| Entity Name | Vascular And Interventional Professionals, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750767745 PECOS PAC ID: 2365758224 Enrollment ID: O20150909000234 |
News Archive
St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.
Direct-to-consumer advertising for commercial genetic testing is on the rise and may be problematic, according to a Massachusetts General Hospital (MGH) physician. In the December issue of Obstetrics & Gynecology, Erin Tracy, MD, MPH, warns that such testing is poorly regulated and may present potential pitfalls for patients and physicians.
The idea of testing blood or urine to find markers that help diagnose or treat disease holds great promise. But as technology has improved to allow researchers to examine tiny fragments of RNA, one major problem has led to limited success.
Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Athanasios Vlahos, MD 911 N Elm St, Ste 128, Hinsdale, IL 60521-3634 Ph: (630) 312-7865 | Athanasios Vlahos, MD 911 N Elm St, Ste 128, Hinsdale, IL 60521-3634 Ph: (630) 856-7460 |
News Archive
St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.
Direct-to-consumer advertising for commercial genetic testing is on the rise and may be problematic, according to a Massachusetts General Hospital (MGH) physician. In the December issue of Obstetrics & Gynecology, Erin Tracy, MD, MPH, warns that such testing is poorly regulated and may present potential pitfalls for patients and physicians.
The idea of testing blood or urine to find markers that help diagnose or treat disease holds great promise. But as technology has improved to allow researchers to examine tiny fragments of RNA, one major problem has led to limited success.
Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.
› Verified 7 days ago
Dr. Judith Ann Operchal, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 120 N Oak St, Hinsdale, IL 60521 Phone: 630-856-9000 | |
Dr. Peter Hrabski, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 120 N Oak St, Hinsdale, IL 60521 Phone: 630-856-9000 | |
Jonathan P. Nolan, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 40 S Clay St # Ll10, Hinsdale, IL 60521 Phone: 630-432-6848 | |
Dr. William G. Fischer Jr., M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 617 S Washington St, Hinsdale, IL 60521 Phone: 630-325-7814 | |
Dr. George Behrens, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 911 N Elm St, Ste 128, Hinsdale, IL 60521 Phone: 630-856-7460 | |
Dr. Daniel Justus, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 120 N Oak St, Hinsdale, IL 60521 Phone: 630-856-9000 | |
Dr. Patrick J Sweeney, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Salt Creek Ln, Amita Health Cancer Institute, Hinsdale, IL 60521 Phone: 630-286-5500 Fax: 630-856-7385 |